Communiqués Ionis Pharmaceuticals, Inc.

Actions

IONS

US4622221004

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2026			Varia. 5j.	Varia. 1 janv.
73,28 ^USD	-0,74%		-2,47%	-7,38%

10/06	Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 08:40 AM
08/06	Ionis Pharmaceuticals, Inc. annonce la nomination de Ludwig Hantson, Ph.D., à son conseil d'administration, à compter du 8 juin 2026	CI

Communiqués

08/06	Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors	BU
05/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia at upcoming congresses	AQ
04/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses	BU
28/05	Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	BU
14/05	Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease	BU
04/05	Ionis to host 2026 virtual Annual Meeting of Stockholders	BU
01/05	Ionis to present at upcoming investor conferences	BU
29/04	Ionis Pharmaceuticals : Q1 2026 Ionis Earnings Slides	PU
29/04	Ionis Pharmaceuticals: Q1 Earnings Snapshot	AQ
29/04	Ionis reports first quarter 2026 financial results and highlights progress on key programs	BU
28/04	Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B	BU
21/04	Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting	BU
15/04	Ionis to hold first quarter 2026 financial results webcast	BU
23/03	Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review	BU
09/03	Ionis announces changes to Board of Directors	BU
02/03	Ionis to present new data supporting DAWNZERA in hereditary angioedema at 2026 AAAAI Annual Meeting	AQ
27/02	Ionis Pharmaceuticals : Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study	PU
27/02	Ionis Pharmaceuticals : Patient Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS HAE	PU
27/02	Ionis Pharmaceuticals : Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis	PU
27/02	Ionis Pharmaceuticals : Real world Adherence and Persistence with Long term Prophylaxis among Patients with Hereditary Angioedema	PU
27/02	Ionis Pharmaceuticals : Rethinking Severity Assessment in Hereditary Angioedema Insights from Patient Experiences	PU
27/02	Ionis Pharmaceuticals : Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema 1 Year Results From OASISplus	PU
27/02	Ionis Pharmaceuticals : The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen	PU
27/02	Ionis Pharmaceuticals : Unmet Treatment Need in a Real World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long Term Prophylaxis	PU
27/02	Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting	BU